PROC and Sepsis: Recombinant human activated protein C (rhAPC) was previously available as drotrecogin alpha (activated) (Xigris, Eli Lilly & Company, Indianapolis, IN) and approved for treatment of sepsis in patients with high risk of death by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMEA) based on results obtained from the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study [3].